DMK Pharmaceuticals's revenue per share for the
three
months ended in Sep. 2023 was $0.00.
DMK Pharmaceuticals's revenue per share for the trailing twelve months (TTM) ended in Sep. 2023 was $1.67.
Warning Sign:
DMK Pharmaceuticals Corp revenue per share has been in decline for the last 5 years.
During the past 12 months, the average Revenue Per Share Growth Rate of DMK Pharmaceuticals was 133.00% per year.
During the past 3 years, the average Revenue Per Share Growth Rate was -57.60% per year.
During the past 5 years, the average Revenue Per Share Growth Rate was -51.80% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate.
The historical rank and industry rank for DMK Pharmaceuticals's Revenue per Share or its related term are showing as below:
DMKPQ'
s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -76.1 Med: -12.5 Max: 105.7
Current: -57.6
During the past 13 years, DMK Pharmaceuticals's highest 3-Year average Revenue Per Share Growth Rate was 105.70% per year. The lowest was -76.10% per year. And the median was -12.50% per year.
DMKPQ's 3-Year Revenue Growth Rate is ranked worse than 98.27% of 923
companies
in the Drug Manufacturers industry
Industry Median: 6.4
vs DMKPQ: -57.60
DMK Pharmaceuticals Revenue per Share Historical Data
The historical data trend for DMK Pharmaceuticals's Revenue per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of DMK Pharmaceuticals's Revenue per Share
For the Drug Manufacturers - Specialty & Generic subindustry, DMK Pharmaceuticals's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
DMK Pharmaceuticals's PS Ratio Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, DMK Pharmaceuticals's PS Ratio distribution charts can be found below:
* The bar in red indicates where DMK Pharmaceuticals's PS Ratio falls into.
DMK Pharmaceuticals Revenue per Share Calculation
Revenue per Share is the amount of Revenue per outstanding share of the company's stock.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
DMK Pharmaceuticals's Revenue Per Share for the fiscal year that ended in Dec. 2022 is calculated as
Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.67
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DMK Pharmaceuticals (OTCPK:DMKPQ) Revenue per Share Explanation
In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.
Peter Lynch categorized companies according to their revenue growth:
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
DMK Pharmaceuticals Revenue per Share Related Terms
Thank you for viewing the detailed overview of DMK Pharmaceuticals's Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
DMK Pharmaceuticals (DMK Pharmaceuticals) Business Description
DMK Pharmaceuticals Corp Formerly Adamis Pharmaceuticals Corp is a specialty biopharmaceutical company focused on developing and commercializing products in various therapeutic areas, including allergy, opioid overdose, respiratory and inflammatory disease. Its products and product candidates in the allergy, respiratory, and opioid overdose markets include SYMJEPI (epinephrine) Injection 0.3mg and Injection 0.15mg for use in the emergency treatment of acute allergic reactions, including anaphylaxis; a naloxone injection product candidate, ZIMHI, based on the approved Symject injection device and intended for the treatment of opioid overdose; Tempol, an investigational drug; and a Beclomethasone metered dose inhaler product candidate (APC-400) intended for the treatment of Covid-19.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
DMKPQ has been successfully added to your 